Latest news with #HSV
Time of India
2 days ago
- Entertainment
- Time of India
Kannada writer HS Venkateshamurthy, 80, passes away
Bengaluru: Renowned Kannada professor and writer HS Venkateshamurthy passed away at a hospital here Friday morning due to age-related health complications. He was 80. Hodigere Shanbhog Venkateshamurthy – and more popular as his initials, HSV – wore many hats encompassing literary, music and cinema worlds. Born in a remote hamlet of Hodigere in Channagiri taluk of Davanagere district in 1944, HSV obtained a master's degree in Kannada at Central College, Bengaluru, and a doctorate in Kannada literature. He was influenced by traditional artforms, including Yakshagana and Bayalaata, along with the works of literary giants Kuvempu, DR Bendre, Masti Venkatesha Iyengar, Shivaram Karanth and Gorur Ramaswamy Iyengar, among others. HSV credited KS Nisar Ahmed, eminent poet from the Navya movement, as his 'poetic guru'. Starting his literary journey with an anthology of poems 'Parivrutha', HSV dedicated the work to his Kannada teacher Narasimha Shastri. His creativity -- shaped by memories of vibrant rustic life, forts, and forests -- helped him blend the two phases (early and later) of Navya literature of Kannada. While some stories were successfully depicted on the silver screen, HSV's story, screenplay, and songs in the Kannada movie 'Chinnari Mutha' won a national film award. Subsequently, HSV wrote songs for 'Kotreshi Kanasu' (which also won an award), and 'America, America', 'Mythri', Shetty starrer 'Kirik Party', and recent movie 'Sapta Sagaradaache Ello, Side-B'. The title track of Kannada's famous tele serial 'Mukta', and songs such as 'Lokada Kannige Radheyu kooda…', 'Yeke Baradiruve Nanna Murali Mohana', 'Huchhu Kodi Manasu…', are hugely popular. He had won awards from Central Sahitya Akademi, Karnataka Sahitya Academy, 66th Filmfare South award for the best song, and Rajyotsava award. He chaired the 85th Kannada literary meeting in Kalaburagi in 2019. CM Siddaramaiah said HSV's death is a huge loss to the Kannada literary world. HSV was cremated with state honours in Bengaluru.
Associated Press
3 days ago
- Business
- Associated Press
Theralase(R) 1Q2025 Financial Statements
Toronto, Ontario--(Newsfile Corp. - May 30, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ('Theralase®" or the 'Company'), a clinical stage pharmaceutical company pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses has released the Company's unaudited interim consolidated 1Q2025 financial statements ('Financial Statements'). Theralase® will be hosting a conference call on Monday June 9 th, 2025 at 11:00 am ET, which will include a presentation of the financial and operational results for the fiscal quarter ending March 31 st, 2025. Questions are welcome; however, to ensure we have time to review and properly address them during the call, please send them in advance to [email protected]. An archived version will be available on the website following the conference call. Financial Summary: For the three-month period ended March 31 st: [ This image cannot be displayed. Please visit the source: ] 1 Other represents foreign exchange, interest accretion on lease liabilities and / or interest income To view an enhanced version of this graphic, please visit: Financial Highlights For the three-month period ended March 31, 2025: Operational Highlights Private Placements The Company has raised approximately $CAN 6.3 million over the last 2 years through non-brokered private placements in support of its research and development programs. It is currently investigating the use of a full-service investment bank in the United States to advise on potential financings and US listing opportunities. Information on any future financings will be released once available in accordance with applicable securities laws. Herpes Simplex Virus ('HSV') Treatment Program Theralase® continues preclinical development of its HSV treatment using non-light activated and light-activated small molecules. The Company is actively working on in-vitro, and in the near future, in-vivo HSV preclinical models to finalize a formulation for optimal dermal penetration to increase patient safety and efficacy. Good Laboratory Practice ('GLP') toxicology studies will commence once a formulation has been finalized. Additional details will be announced as strategic objectives are achieved. Phase II Bladder Cancer Study Update ('Study II') Interim Clinical Results For the primary endpoint of Study II (Complete Response ('CR') at any point in time) 62% of patients provided the Study Procedure (Study Drug activated by the Study Device) demonstrated a CR. Including patients, who demonstrated an Indeterminate Response ('IR') (negative cystoscopy and positive or suspicious urine cytology), the Total Response ('TR') increases to 70%. This represents that approximately 2 out of 3 BCG-Unresponsive NMIBC CIS patients treated with Theralase®'s unique Study Procedure are demonstrating complete destruction of their bladder cancer. For the secondary endpoint of Study II (duration of CR) 42% of treated patients who achieved a CR, maintained their CR response for at least 12 months (450 days from date of Study Procedure). For the tertiary endpoint of Study II (safety of Study Procedure) 100% (69/69) experienced no Serious Adverse Events ('SAEs') directly related to the Study Drug or Study Device. Outside of the defined endpoints of Study II, Theralase® has demonstrated a duration of CR at extended time points of 23% at 2 years, 21% at 3 years and 2% at 7 years. Note: Not all patients have been assessed at these extended time points. As more clinical data is collected, the duration of CR at 2, 3 and 7 years may increase. Theralase® is on track to complete enrollment in Study II by the summer of 2025. This will allow the Company to report on 75 patients who have completed Study II in December 2025 and to report on all 90 patients by September 2026. Upon follow-up of all patients, the Company plans to submit a New Drug Application ('NDA') to Health Canada and the FDA in 4Q2026, with a decision expected by the respective regulatory authorities on a marketing approval in 2027. As Theralase® completes enrollment in Study II, it is actively searching for commercialization partners for international marketing and sales of Ruvidar®. To this end, Theralase® is in various stages of initial and advanced discussions with international pharmaceutical companies for various geographical territories concerning: In recent discussions with the FDA, the Company has decided that since Study II is 91% complete, the best course of action is not to pursue Break Through Designation, but to complete Study II and submit the clinical data to the FDA in a formal NDA. At the end of the meeting, the FDA made a comment that they were impressed that the interim clinical data obtained to date was able to be achieved with only one clinical treatment, in the majority of cases. Ruvidar® has demonstrated 10 years of shelf life, strongly supporting the stability of the molecule and the ability of clinics to store the small molecule for extended periods of time. Additional Oncology Targets Theralase® has combined Ruvidar® with transferrin (human glycoprotein) to form Rutherrin®. Rutherrin® is a strong candidate for the systemic treatment of recurrent, deep seated and/or progressive cancers. Due to the limitations of using laser light to activate Rutherrin® in deep oncological targets, Theralase® plans to activate Rutherrin® with radiation therapy to increase the 'tumour's damage zone' and the effectiveness of Theralase®'s small molecule beyond the reach of light in the body. Rutherrin®, if clinically proven, will be able to 'hunt' and 'localize' into cancer cells and when activated by radiation 'destroy' them; wherever, they may reside in the body. The Company expects to complete Good Laboratory Practice toxicology analysis in 4Q2025 to allow commencement of a Phase 0/I/II adaptive clinical study in 1Q2026 for the following indications: 1) Glio Blastoma Multiforme ('GBM') Brain Cancer Treatment 2) Non-Small Cell Lung Cancer ('NSCLC') Treatment 3) Pancreatic Cancer 4) Colorectal Cancer 5) Muscle Invasive Bladder Cancer ('MIBC') Treatment 6) Herpes Simplex Virus ('HSV-1") Topical Treatment for Cold Sore Lesions For additional information, please refer to the Company's Management's Discussion and Analysis ('MD&A') available at About Ruvidar®: Ruvidar®(TLD-1433) is a small molecule, able to be activated by light, radiation, sound and/or other drugs, intended for the safe and effective destruction of various cancers, bacteria and viruses. About Theralase® Technologies Inc.: Theralase® is a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecule compounds, their associated drug formulations and the light systems that activate them, with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses. Additional information is available at and Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Forward-Looking Statements: This news release contains Forward-Looking Statements ('FLS') within the meaning of applicable Canadian securities laws. Such statements include; but, are not limited to statements regarding the Company's proposed development plans with respect to small molecules and their drug formulations. FLS may be identified by the use of the words 'may, 'should', 'will', 'anticipates', 'believes', 'plans', 'expects', 'estimate', 'potential for' and similar expressions; including, statements related to the current expectations of the Company's management regarding future research, development and commercialization of the Company's small molecules; their drug formulations; preclinical research; clinical studies and regulatory approvals. These statements involve significant risks, uncertainties and assumptions; including, the ability of the Company to fund and secure the regulatory approvals to successfully complete various clinical studies in a timely fashion and implement its development plans. Other risks include: the ability of the Company to successfully commercialize its small molecule and drug formulations; the risk that access to sufficient capital to fund the Company's operations may not be available on terms that are commercially favorable to the Company or at all; the risk that the Company's small molecule and drug formulations may not be effective against the diseases tested in its clinical studies; the risk that the Company fails to comply with the terms of license agreements with third parties and as a result loses the right to use key intellectual property in its business; the Company's ability to protect its intellectual property; the timing and success of submission, acceptance and approval of regulatory filings. Many of these factors that will determine actual results are beyond the Company's ability to control or predict. Readers should not unduly rely on these FLS, which are not a guarantee of future performance. There can be no assurance that FLS will prove to be accurate as such FLS involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the FLS are made as of the date hereof and are subject to change. Except as required by law, the Company assumes no obligation to update such FLS. For investor information on the Company, please feel to reach outInvestor Inquiries - Theralase Technologies. For More Information: (843-5273) (5273) Kristina Hachey, CPA Chief Financial Officer X 224 [email protected] To view the source version of this press release, please visit
Time of India
3 days ago
- Entertainment
- Time of India
Kannada literary icon HS Venkatesh Murthy passes away at 80
Picture Credit: Facebook HS Venkatesh Murthy, a towering figure in Kannada literature and cinema, passed away peacefully in the early hours of May 30, 2025, at the age of 80. As per a report by Bangalore Times, he had been battling age-related health issues and was admitted to a private hospital in Kengeri, Bengaluru, before his demise. Born on June 23, 1944, HSV was not only a prolific writer but also a dedicated educator. He spent over three decades teaching at St. Joseph's College of Commerce in Bengaluru, where he served as a lecturer and professor. During his academic career, he earned a doctorate, further cementing his commitment to education and scholarship. As a literary stalwart, HSV authored more than 100 books in Kannada, spanning various genres including poetry, novels, and plays. His contributions to Kannada literature were vast and influential. One of his notable plays, Hoovi, gained special recognition when it was included in the ICSE curriculum for ninth and tenth-grade Kannada students, helping introduce young learners to quality literature. Beyond the realm of books, HSV made significant marks in Kannada cinema and television. He was a gifted lyricist, penning memorable songs that resonated with audiences. Among his popular works is the song 'Thoogu Manchadalli Koothu' from the hit film 'Kirik Party', starring Rashmika Mandanna . by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like American Investor Warren Buffett Recommends: 5 Books For Turning Your Life Around Blinkist: Warren Buffett's Reading List Undo He composed songs and wrote dialogues for several acclaimed Kannada films such as 'Chinnari Mutha', 'Kotreshi Kanasu', 'America America' and 'Maithri'. HSV's talent earned him numerous awards throughout his lifetime. Notably, he received the Bala Puraskar Award from the Central Sahitya Akademi, recognizing his contribution to children's literature. HS Venkatesh Murthy's passing is a profound loss to the Kannada literary and film communities. Check out our list of the latest Hindi , English , Tamil , Telugu , Malayalam , and Kannada movies . Don't miss our picks for the best Hindi movies , best Tamil movies, and best Telugu films .
Time of India
3 days ago
- Entertainment
- Time of India
Kannada literary giant HS Venkateshamurthy (HSV) passes away in Bengaluru
BENGALURU: Renowned Kannada professor, poet, playwright, lyricist, novelist, translator, and critic HS Venkateshamurthy passed away in Bengaluru on Friday morning. Murthy, aged 80, was admitted to a private hospital in Kengeri due to age-related health complications and breathed his last at around 7 am in Bengaluru. He is survived by four sons. Several of his works, including stories, songs, and screenplay-dialogues, won state and national awards. Melodious songs from the national award-winning children's film 'Chinnari Mutha', the song 'Baanalli Odo Megha…' from the movie 'America, America', and 'Thoogumachadalli Kootu…' from the blockbuster movie 'Kirik Party' were penned by Venkateshamurthy. Academically known as Dr Hodigere Shanbhog Venkateshamurthy, he was fondly referred to as 'HSV' by his initials in the literary, music, and cinema worlds. Born in a remote hamlet of Hodigere in Channagiri taluk of Davanagere district in 1944, HSV obtained a master's degree in Kannada at the Central College Bengaluru and a PhD in Kannada literature. Working as a professor of Kannada at the St Joseph's College of Commerce in Bengaluru, HSV was influenced by traditional art forms, including Yakshagana and Bayalaata, along with the works of Kannada literary giants such as Kuvempu, Bendre, Maasthi, Karanth, Goruru Iyengar, and others. In fact, HSV fondly remembered Prof KS Nissar Ahmed, a prolific writer and poet of the Navya movement of Kannada literature, as his 'poetic guru'. Starting his literary journey with his first anthology of poems 'Parivrutha', HSV dedicated the work to his Kannada teacher Narasimha Shastri, who initiated him into Kannada literature. His creativity, shaped by the memories of rustic rural life, forts, nature, forests, rivers, and bustling markets, helped him blend the two phases (early and later) of popular Navya Literature of Kannada. Some of his poetic works include 'Onada Marada Giligalu', 'Sougandhika', 'Elegalu Nooraru', 'Agni Sthamba', and 'Eshtondu Mukha'. His translation work 'Rutuvilasa', based on the classical writer of Sanskrit Kavirathna Kalidasa's 'Rutusamhara', won accolades in literary circles. He penned hundreds of anthologies, short stories, and novels, and plays, and HSV forayed into Kannada theatre and cinema. While some of his stories were successfully depicted on the silver screen, HSV's story, screenplay, and songs in the movie 'Chinnari Mutha' won a national film award. Subsequently, HSV wrote songs for yet another award-winning movie 'Kotreshi Kanasu', Ramesh Aravind starrer 'America, America', Puneeth Rajkumar starrer 'Mythri', Rakshit Shetty starrer 'Kirik Party', and the recent blockbuster 'Sapta Sagaradaache Ello, Side-B'. His poems, set to tune by renowned musicians including C Ashwath, Raju Ananthaswamy, and others, have become popular songs in the Kannada light music world. The title track of Kannada's famous tele serial 'Mukta', and songs such as 'Lokada Kannige Radheyu kooda…', 'Yeke Baradiruve Nanna Murali Mohana', 'Huchhu Kodi Manasu…', 'Amma Naanu Devarane Benne Kaddilla….', and 'Aidu Beralu Koodi Mushtiyu…' (National diversity) were some of his all-time popular songs sung by many. His literary journey across fields brought him several recognitions, awards, and accolades, including the Kendra Sahitya Academy, Karnataka Sahitya Academy, the 66th Filmfare South award for the best song, and the Rajyotsava award. He chaired the 85th All India Kannada Sahitya Sammelana as President at Kalaburagi in 2019.
Pink Villa
3 days ago
- Entertainment
- Pink Villa
Kirik Party lyricist and notable Kannada writer HS Venkatesh Murthy passes away at 80
Trigger Warning: This article contains mention of death. HS Venkatesh Murthy remained one of the legendary figures of Kannada literature and cinema over the years. He was a talented professor, dialogue writer, lyricist, poet, novelist, and had many other areas of expertise to his name. The literary stalwart has now passed away at the age of 80. HS Venkatesh Murthy dies at 80 As per reports, HSV was suffering from age-related geriatric issues. He was 80 and passed away in the early morning hours of May 30, 2025. He had been admitted to a private hospital in Kengeri, Bengaluru. The news of his demise is being mourned across literary circles and the Kannada film industry. His passing leaves a void, marked by the incredible creations he leaves behind. HS Venkatesh's career so far Born in 1944, HS Venkatesh Murthy worked as a lecturer and professor for over three decades at St. Joseph's College of Commerce. He also earned his doctorate during this time in Bengaluru. As a writer, HSV published over 100 books in Kannada. One of his plays, Hoovi, was even selected as part of the ICSE curriculum for ninth and tenth-grade students studying Kannada. HSV's contributions to films Besides books and literature, HS Venkatesh Murthy also made significant contributions to Kannada cinema and television serials. He worked as a lyricist for several popular film songs, including the track Thoogu Manchadalli Koothu from the Rashmika Mandanna -starrer Kirik Party. HS Venkatesh's awards Among the many awards and accolades he received, the senior writer was honored with the Bala Puraskar Award from the Central Sahitya Akademi. He also won the Filmfare Award for Best Lyricist – Kannada for his work on the movie Hasiru Ribbon in 2018-19.
